C1 esterase inhibitor-mediated immunosuppression in COVID-19: Friend or foe?

From asymptomatic to severe, SARS-CoV-2, causative agent of COVID-19, elicits varying disease severities. Moreover, understanding innate and adaptive immune responses to SARS-CoV-2 is imperative since variants such as Omicron negatively impact adaptive antibody neutralization. Severe COVID-19 is, in...

Descripción completa

Detalles Bibliográficos
Autores principales: Hausburg, Melissa A., Williams, Jason S., Banton, Kaysie L., Mains, Charles W., Roshon, Michael, Bar-Or, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Inc. 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9068237/
https://www.ncbi.nlm.nih.gov/pubmed/38013973
http://dx.doi.org/10.1016/j.clicom.2022.05.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9068237/
https://www.ncbi.nlm.nih.gov/pubmed/38013973
http://dx.doi.org/10.1016/j.clicom.2022.05.001

Ejemplares similares